« Return to News | Study Conduct

Cardio3 establishes US subsidiary

Friday, September 23, 2011 10:35 AM

Belgian cardiac cell therapies firm Cardio3 BioSciences established a U.S. subsidiary in Rochester, MN, to support its clinical and development activities and to bolster existing links with the Mayo Clinic and other U.S. collaborators, according to GEN News. Cardio3’s lead product, C3BS-CQR-1 is a stem cell-based cardiac lineage in clinical development for the treatment of heart failure. Phase III studies are projected to start in 2012.

Having a base in the U.S. will allow the firm to substantiate early evidence of the feasibility, safety, and efficacy of C-Cure in a larger-scale setting, including phase III studies, and strengthen its ongoing research and commercialization relationship with the Mayo Clinic, which developed the cardiopoiesis technology on which Cardio3’s platform has been built.

Founded in 2007, Cardio3 is focused on the development of regenerative and protective therapies for the treatment of cardiac disease. Lead product candidate C-Cure is based on a patient’s own bone marrow stem cells, which are treated with a cardiopoietic cocktail before being re-injected into the heart to generate heart muscle cells. The firm says the treatment acts both directly, through the proliferation, engraftment, and terminal differentiation of the injected cells, as well as indirectly, through the beneficial effect on the patient’s existing cardiac stem cells of factors secreted by the transplanted cells.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.